Elanco Animal Health reported revenue of $1,265 million for the third quarter of 2026, an increase from $1,137 million in the prior year. The company achieved a net income of $18 million for the quarter, recovering from a net loss of $34 million in Q3 2025, driven by higher gross profits and lower restructuring charges.
Elanco Animal Health reported Q3 2026 revenue of $1.265 billion, an 11% increase year-over-year, driven by strong demand for its 'Big 6' innovation products. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted EPS while achieving a net leverage ratio milestone of 2.9x.
Term
Q3 2026
“Third quarter results demonstrate Elanco is a consistent, reliable growth company, delivering our diverse portfolio of innovation along with accelerating cash flow.”
Jeff Simmons, President and CEO of Elanco
“Organic constant currency revenue growth of 9% was led by International Pet Health up 17% and U.S. Pet Health up 13%, as we saw strong veterinarian and pet owner demand for what we believe is 'best medicine' innovation for our 'Big 6' growth led by Zenrelia and Credelio Quattro.”